Advertisement


William A. Wood, MD, MPH, on the New ASH Research Collaborative Data Hub COVID-19 Registry for Hematologic Malignancy

COVID-19 and Cancer Care

Advertisement

William A. Wood, MD, MPH, of the University of North Carolina at Chapel Hill, and Oversight Group Chair for the new COVID-19 registry, talks about why it was formed, how it can help patients and providers, and how it operates and could evolve in the future. Filmed April 3, 2020.



Related Videos

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 2

Are you treating patients with advanced chronic myeloid leukemia (accelerated phase or blast crisis) any differently during the COVID-19 pandemic?

Recorded April 24, 2020.

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 1

How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?

Recorded April 24, 2020.

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 6

Are you proceeding with front-line autologous transplant in patients with mantle cell lymphoma or delaying it during the COVID-19 pandemic?

Recorded April 21, 2020.

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 5

For community oncologists treating patients with multiple myeloma during the COVID-19 pandemic, what resources and clinical pearls would you suggest?

Recorded April 24, 2020.

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 3

Because of the COVID-19 pandemic, has your management strategy changed for post-transplant consolidation and maintenance therapy in patients with multiple myeloma?

Recorded April 24, 2020.

Advertisement

Advertisement




Advertisement